Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDURA-1: Depemokimab in COPD with type 2 inflammation
CTR20253006Phase 3Active
- Sponsor
- GSK
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of depemokimab in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Nov 2025; status: active.
02
Drugs
depemokimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20253006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253006.